Controversy in multiple myeloma transplants: Tandem autotransplants and mini-allografts

Bone Marrow Transplantation

Volumn 28, Issue 8, 2001, Pages 725-735

  Vesole, D H ^a   Simic, A ^b   Lazarus, H M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic transplant; Autologous transplant; Multiple myeloma; Non myeloablative transplant; Stem cell transplant; Tandem transplant

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; APOPTOSIS INHIBITOR; BRYOSTATIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; MELPHALAN; PREDNISONE; RADIOISOTOPE; THALIDOMIDE; VINCRISTINE;

ALLOGRAFT; AUTOGRAFT; AUTOTRANSPLANTATION; CONTROLLED STUDY; HUMAN; INFORMATION PROCESSING; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PEER REVIEW; PRIORITY JOURNAL; SHORT SURVEY; STANDARD; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035180594     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703254     Document Type: Short Survey

References (108)

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres
3. Thalidomide plus dexamethasone (THAL/DEX) and thalidomide alone (THAL) as first line therapy for newly diagnosed multiple myeloma (MM)
4. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma
5. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma
6. Amifostine (AF) cytoprotection (CP) of escalating doses of melphalan (MEL) and autologous hematopoietic stem cell transplantation (AHSCT): Final results of a phase I and II study
7. 166Holmium-DOTMP plus standard high dose chemotherapy (HDC) with autologous transplant produce high rates of complete remission (CR) in multiple myeloma (MM) patients: An updated report of a phase I/II study
8. 153SM-EDTMP) and melphalan
9. Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma
10. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
11. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation
12. Transfer of myeloma idiotype-specific immunity from an actively immunised donor
13. DNA vaccines against haematological malignancies
14. Novel approaches in myeloma therapy
15. Antitumor activity of thalidomide in refractory multiple myeloma
16. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - A phase 1 study
17. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy
18. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
19. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
20. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
21. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies
22. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
23. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
24. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
25. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
26. Final analysis of total therapy with tandem transplants for 231 newly diagnosed patients with multiple myeloma
27. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
28. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
29. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
30. Total therapy with tandem transplants for newly diagnosed multiple myeloma
31. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
32. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma
33. 2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly myeloma. Preliminary results of the IFM 9502 randomized trial
34. 2 melphalan (TBI + HDM140) as conditioning regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM). Final analysis of the IFM9502 randomized trial
35. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical ransplants with melphalan alone
36. 2522 autotransplants in multiple myeloma: A registry study from the European Group for Blood and Marrow Transplantation (EBMT)
37. Autologous stem cell transplantation in multiple myeloma: The 2000 EBMT registry update
38. Intensive treatment for multiple myeloma: Where do we stand?
39. Beta 2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma
40. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma
41. Prognostic value of bone marrow angiogenesis in multiple myeloma
42. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
43. Effect of complete response on outcome following autologous stem cell transplantation for myeloma
44. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death
45. Age is not a prognostic variable with autotransplants for multiple myeloma
46. Feasibility and efficacy of melphalan-based high dose therapy (MEL-HDT) with autologous peripheral blood stem cell support for patients with multiple myeloma (MM) age ≥ 70 years
47. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients
48. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study
49. High-dose melphalan and autotransplantation in myeloma with renal impairment: A matched-pair comparison with patients without renal failure
50. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant
51. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency
52. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation
53. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant: Results of a phase III study
54. Lack of benefit of CD34 + cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: Results of a single center study
55. + cells to support single or tandem high-dose chemotherapy
56. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
57. + hematopoietic stem cells (HSCs) in multiple myeloma: Impact of HSC dose on engraftment, safety, and immune reconstitution
58. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
59. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of a French Registry on Autologous Transplantation in Multiple Myeloma
60. Double-intensive therapy in high-risk multiple myeloma
61. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
62. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support
63. A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: Results of an interim analysis
64. Single versus double transplantation in myeloma: A prospective randomized trial of the Inter Groupe Francophone du Myelome (IFM)
65. Treatment of multiple myeloma (MM) patients (pts) with tandem autologous stem cell transplantation (ASCT) using high-dose (HD) melphalan (MEL) followed by busulfan (BU)
66. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma
67. The 'Bologna 96' clinical trial of single vs. double PBSC transplantation for previously untreated MM: Results of an interim analysis
68. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: Preliminary results of a two by two designed randomized trial in with multiple myeloma (MM)
69. Single versus double transplant in myeloma: A randomized trial of the 'Inter Groupe Francais Du Myelome' (IFM)
70. Intensive versus double intensive therapy in previously untreated multiple myeloma: A prospective randomized phase III study in 450 patients
71. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
72. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
73. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
74. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
75. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
76. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
77. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
78. Graft-versus-myeloma effect: Proof of principle
79. Graft-versus-myeloma effect in two cases
80. Graft-versus-myeloma
81. Autologous and allogeneic transplantation for multiple myeloma at a single centre
82. Allogeneic bone marrow transplantation in multiple myeloma: Single-center experience of 97 patients
83. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
84. Similar disease-free survival (DFS) after allografting and autografting for multiple myeloma (MM)
85. Progress in allogeneic stem cell transplantation for multiple myeloma over the 90's
86. An overview of allogeneic transplantation in multiple myeloma
87. Outcome of unrelated transplants in patients with multiple myeloma
88. Allogeneic stem cell transplantation for multiple myeloma
89. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
90. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
91. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
92. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
93. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation
94. Adoptive T-cell therapy
95. Graft versus myeloma. Clinical and basic aspects
96. Donor leukocyte infusions for multiple myeloma
97. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
98. Suicide gene therapy for plasma cell tumors
99. Reinventing bone marrow transplantation: Nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect
100. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
101. Toward curing myeloma: Keeping the pressure on tumor cells and the microenvironment with high dose melphalan and thalidomide
102. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience
103. Fludarabine/melphalan regimen results in low treatment related mortality and low relapse in myeloma patients undergoing allogeneic stem cell transplant (BMT)
104. Non-myeloblative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma
105. Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM)
106. Non-myeloablative allograft to induce graft versus myeloma effect after cytoreductive autotransplant for multiple myeloma
107. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects